European Growth Partner Evidenze's recent strategic investment with Columna Capital signals strong funding and a path to scale European healthcare services, presenting an opportunity for sponsors seeking European CRO capabilities and cross-border trial execution. It suggests readiness to support multi-market programs and accelerate market access.

Nephrology Data Opportunity The launch of Nefro Data Space with Hospital Clínic and partners demonstrates Evidenze’s ability to deliver data-centric, nephrology-focused trial infrastructure, enabling real-world data integration and advanced analytics for kidney disease programs, an attractive entry point for nephrology drug developers.

Full Value Edge Evidenze markets a Full Value CRO model combining deep expertise, technology, and strategic insights to accelerate trials, reduce costs, and improve regulatory success, offering a compelling value proposition for sponsors seeking to streamline complex programs across regions.

Hospital Collaboration Edge Strategic collaborations with leading hospitals, such as Hospital Clínic, position Evidenze as a preferred partner for access to clinical sites, patient data, and real-world networks, supporting faster patient recruitment and high-quality trial execution.

Growth Credibility With a scalable mid-market footprint, a global delivery model, and ongoing growth initiatives in Europe, Evidenze carries credibility and momentum that can be leveraged to win new sponsor engagements, expand service offerings, and cross sell data and analytics capabilities.